๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Metastatic Colorectal Cancer
Clinical trial register · China

Metastatic Colorectal Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 8 Shanghai 7 Beijing 7 Wuhan 5 Hefei 4
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou8 Shanghai7 Beijing7 Wuhan5 Hefei4
All 30 locations
Target enrolment
to

Metastatic Colorectal Cancer trials in China

32 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412Metastatic Colorectal Cancer
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Guangzhou, Nanning, Wuhan, Nanjing, Chengdu, Hangzhou
2026-05-06
Recruiting
JS212 Combination Therapies in Metastatic Colorectal Cancer
NCT07503756Metastatic Colorectal Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Shanghai
2026-04-25
Recruiting
Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients
NCT07314294Metastatic Colorectal Cancer
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 2
54
Beijing, Guangzhou
2025-12-18
Recruiting
New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer
NCT07559760Metastatic Colorectal Cancer
The First Hospital of Jilin University
Phase 2
30
Changchun
2025-11-01
Recruiting
Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer
NCT07718490Metastatic Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
43
Nanjing
2025-09-01
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
AstraZeneca
Phase 2
80
Beijing, Chengdu, Harbin, Shanghai, Wuhan, Zhengzhou
2025-03-12
Recruiting
A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer
NCT06979908Metastatic Colorectal Cancer
The First Hospital of Jilin University
Phase 2
46
Changchun
2025-01-22
Recruiting
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
NCT06493760Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
130
Shanghai
2024-09-03
Recruiting
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
NCT06551207Metastatic Colorectal Cancer
Liu Huang
Not applicable
80
Wuhan
2024-08-20
Active, closed
CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer
NCT07801352Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Shanghai Changzheng Hospital
Phase 2
15
Shanghai
2024-07-01
Recruiting
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
NCT06341296Metastatic Colorectal Cancer
West China Hospital
Phase 2
86
Sichuan
2024-06-30
Recruiting
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
NCT06321081RAS Mutation, Metastatic Colorectal Cancer, MSS
Beijing Hospital
Phase 2
60
Beijing
2024-03-01
Recruiting
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
NCT06218810Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab
Fudan University
Phase 2
53
Shanghai
2024-01-01
Not yet open
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
NCT06195670CRC, Metastatic Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
Zhejiang Cancer Hospital
Phase 1/2
220
Hangzhou
2024-01
Recruiting
Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT06776757Metastatic Colorectal Cancer
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 1/2
30
Shenzhen
2023-12-25
Recruiting
MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases
NCT06208397Metastatic Colorectal Cancer
Shengjing Hospital
Observational
50
Shenyang
2023-12-24
Recruiting
Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
NCT05959356Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2
198
Foshan, Guangzhou, Guiyang
2023-11-09
Recruiting
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
NCT06118762Metastatic Colorectal Cancer
The First Affiliated Hospital of Nanchang University
Phase 4
30
Nanchang
2023-10-20
Recruiting
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
NCT05962502Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2
54
Guangzhou
2023-08-24
Recruiting
Second-line Treatment of Metastatic Colorectal Cancer
NCT06242067Metastatic Colorectal Cancer
Qilu Hospital of Shandong University
Phase 2
50
Jinan
2023-04-23
Not yet open
SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC
NCT05747716Metastatic Colorectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
44
Wuhan
2023-02-28
Active, closed
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
NCT05652894Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3
190
Bengbu, Fuyang, Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou
2023-02-28
Recruiting
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
NCT06202001Metastatic Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
70
Beijing
2022-10-01
Active, closed
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
NCT05382442Metastatic Colorectal Cancer
Akeso
Phase 2
254
Guanzhou
2022-06-27
Active, closed
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Mirati Therapeutics Inc.
Phase 3
461
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-24
Active, closed
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
NCT04854668Metastatic Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
748
Chizhou, Fuzhou, Hefei, Xuancheng, Beijing, Chongqing, Xiamen, Lanzhou
2021-05-27
Recruiting
A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
NCT06749015Metastatic Colorectal Cancer, BRAF V600 Mutation
Fudan University
Observational
100
Shanghai
2021-03-01
Rows per page Showing 1–32 of 32
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/metastatic-colorectal-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 32 of those studies listing the condition Metastatic Colorectal Cancer.

How many Metastatic Colorectal Cancer trials are recruiting in China?

23 of the 32 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Metastatic Colorectal Cancer), 32 studies
PhaseStudiesRecruitingShare
Phase 2161350%
Phase 37221.9%
Phase 1/24312.5%
Observational226.3%
Not applicable113.1%
Phase 2/3113.1%
Phase 4113.1%

Most active sponsors

Lead sponsors with the most studies (Metastatic Colorectal Cancer)
Lead sponsorStudiesRecruiting
Fudan University22
Liu Huang22
Sun Yat-sen University22
The First Hospital of Jilin University22
AbbVie10
Akeso10
Amgen11
AstraZeneca11
Beijing Hospital11
Bristol-Myers Squibb10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.